Curing Cancer: Advancements and What is Yet to Come
10 February 2017
Last month, MIT Technology Review reported “Two Infants Treated with Universal Immune Cells Have Their Cancer Vanish.” UK doctors treated the babies with genetically engineered T-cells from another person, known as CAR-T, as recounted in Science Translational Medicine.
Syndax Appoints Richard P. Shea as Chief Financial Officer
09 February 2017
Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced that Richard P. Shea is stepping down from his position on the Syndax Board of Directors and is joining the Company as Chief Financial Officer.
Does Pharma Really Want to Overhaul FDA?
08 February 2017
In a much-publicized White House meeting this week with top biopharma executives, President Donald Trump promised to “streamline” FDA operations to speed up approval decisions on new drugs and medical products. Market-based reforms, he said, would inject more competition into prescription drug markets and help lower prices. Leading industry executives smiled and applauded, largely hoping to defuse the President’s call for Medicare drug price negotiations. But the attack on FDA rules and processes could be more damaging.
Biotech leaders take on Trump’s immigration ban, warn of mounting harm
08 February 2017
More than 160 biotech and VC execs have signed a strongly worded letter in Nature Biotech today denouncing President Donald Trump’s recent three-month immigration executive order that has delayed or banned some travelers from across seven predominantly Muslim countries trying to enter the U.S.
Do Social Ties Affect Our Health?
08 February 2017
Cuddles, kisses, and caring conversations. These are key ingredients of our close relationships. Scientists are finding that our links to others can have powerful effects on our health. Whether with romantic partners, family, friends, neighbors, or others, social connections can influence our biology and well-being.
QuintilesIMS: Lifetime Trends in Biopharmaceutical Innovation
08 February 2017
A total of 667 innovative biopharmaceuticals launched in the U.S. over the past 20 years, 1996-2015, bringing new treatment options to patients. After a low point of only 19 NAS launches in 2008, the number has steadily increased and reached 47 in 2015. The characteristics of biopharmaceutical innovation have also evolved over the past two decades, with increases in the share of cancer treatment launches from 11% to 28%, orphan indications from 21% to 42% and biologic launches.
This is not a video game: New TV ad showcases the destruction of a cancer cell by immune system
07 February 2017
Today, as part of our new advertising and public affairs initiative, GOBOLDLY, we are excited to announce the premier of our newest TV advertisement, Cells, which highlights innovative immunotherapy treatments by America’s biopharmaceutical companies.
The Value Collaborative: Advancing private market solutions to achieve better health, lower costs
07 February 2017
Each day, biopharmaceutical researchers push the bounds of medical science to find new treatments and cures to the most complex conditions facing patients. The launch of GOBOLDLY, our new national, multi-year initiative brings those bold, life-changing medical discoveries to the forefront. Yet, at the core of this effort is also our responsibility to make our health care system more responsive to the needs of patients.
Immunotherapy treatment fast-tracked under UK’s access to medicines scheme
07 February 2017
This is following a positive Scientific Opinion by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), under the Early Access to Medicines Scheme (EAMS), that allows patient and doctors access to innovative treatments for serious medical conditions where there is a clear current unmet medical need, whilst they are being fully assessed for Marketing Authorisation.
Pfizer Reacts to Trump’s Comments and Discusses Pipeline in Its Q4 Earnings Call
06 February 2017
Pfizer executives were not among the pharma representatives who met with Trump yesterday to discuss various issues affecting the industry, a circumstance that Pfizer attributed to a schedule conflict with its quarterly earnings call. Despite the company’s absence from the meeting, Pfizer’s CEO Ian C. Read commented on some of Trump’s policy suggestions, and also discussed sales trends and projections for Pfizer’s R&D pipeline.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Russia has expanded the mandatory health insurance program for 2024-2026
29 March 2024
Russian scientists have developed new TB vaccines for both injection and nasal administration.
29 March 2024
The overall mortality rate of the population in Russia decreased by 7% in 2023
28 March 2024
Russia to collaborate with Hungary and Serbia in nuclear medicine
28 March 2024